PROSPECTS FOR THE TREATMENT OF IDIOPATHIC AND NEUROGENIC OVERACTIVE BLADDER
- Autores: Kamalov A.A1, Korshunova E.S2, Popov G.R2, Khodyreva L.A3, Dudareva A.A.3, Nizov A.N3
-
Afiliações:
- Medical Research and Education Center of Moscow State University n.a. M.V. Lomonosov
- Research and Practice Neuropsychiatric Center n.a. Z.P. Solovyov
- Moscow State University n.a. M.V. Lomonosov
- Edição: Nº 1 (2015)
- Páginas: 30-35
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280385
- ID: 280385
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
A. Kamalov
Medical Research and Education Center of Moscow State University n.a. M.V. Lomonosov
E. Korshunova
Research and Practice Neuropsychiatric Center n.a. Z.P. SolovyovMoscow
G. Popov
Research and Practice Neuropsychiatric Center n.a. Z.P. SolovyovMoscow
L. Khodyreva
Moscow State University n.a. M.V. Lomonosov
Email: khodyreva60@mail.ru
Department of Urology and Andrology of Faculty of Fundamental Medicine; MD, Associate Professor
A. Dudareva
Moscow State University n.a. M.V. LomonosovDepartment of Urology and Andrology of Faculty of Fundamental Medicine
A. Nizov
Moscow State University n.a. M.V. LomonosovDepartment of Urology and Andrology of Faculty of Fundamental Medicine
Bibliografia
- Пушкарь Д.Ю., Касян Г.Р. Функциональная урология и уродинамика: монография. М.: ГЭОТАР-Медиа, 2013. 376 с.
- Stewart W.F., VanRooyen J.B., Cundiff G.W. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003;20:327-336.
- Irwin D.E., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006;50(6):1306-1314.
- Brown J.S., McGhan W.F., Chokroverty S. Comorbidities associated with overactive bladder. Am. J. Manag. Care. 2000;6(11 Suppl): S574-579.
- EAU Guidelines, 2014. http://www.uroweb.org/gls/pdf/20%20 Urinary%20Incontmence_LR.pdf
- Ohtake A., Ukai M., Hatanaka T. et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. 2004; 492:243-250.
- Ohtake A., Sato S., Sasamata M. et al. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J. Pharmacol. Sci. 2010;112(2):135-141.
- Haab F, Cardozo L, Chappie C. et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. 2005; 47(1):43-45.
- Govier F.E., Smith N., Uchida T. Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo- Controlled Phase III Pivotal Trial. Clinical Medicine Insights: Urology. 2010;4:11-20.
- Cardozo L, Amarenco G., Pushkar D. et al. SUNRISE Study Group. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJUInt. 2013;111(5):804-810.